Intravenous thrombolysis versus early antiplatelet therapy in acute ischaemic stroke with small artery occlusion
Open Access
- 25 September 2025
- journal article
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 11 (3)
Abstract
Background: The efficacy of intravenous thrombolysis (IVT) versus early antiplatelet therapy (APT) in small artery occlusion (SAO) stroke remains debated. Methods: Ischaemic stroke (IS) patients with SAO who received IVT or early APT without IVT≤4.5 hours from stroke onset were screened from a prospective multicentre IS registry study from 1 January to 1 June 2021. The primary outcome was unfavourable functional outcome (FO) at 3 months. The secondary outcome was early neurological deterioration (END). The safety outcome was symptomatic intracerebral haemorrhage (sICH). Results: There were 1125 SAO patients with 394 receiving IVT. 411 patients (36.5%) exhibited unfavourable FO, and sICH occurred in 3 cases (0.27%), all in IVT group, at the follow-up. END was observed in 213 patients (18.9%). After propensity score matching and multivariable adjustment, IVT significantly reduced the likelihood of unfavourable FO at 3 months (aOR 0.447, 95% CI 0.305 to 0.656), but no significant difference was found in END (aOR 0.867, 95% CI 0.569 to 1.321). Clustering analysis identified two distinct phenotypes: phenotype 0 (characterised by traditional cardiovascular risk factors) and phenotype 1 (marked by prominent inflammatory markers). A significant treatment-by-phenotype interaction was observed (p=0.002), with a comparable magnitude of benefit in phenotype 0 (aOR 0.405, 95% CI 0.244 to 0.673) compared with phenotype 1 (aOR 0.414, 95% CI 0.218 to 0.783). Conclusion: IVT significantly reduced the likelihood of unfavourable FO at 3 months in SAO patients but did not significantly reduce END. Patients with traditional risk factors may benefit more from IVT than those with elevated inflammatory markers. Trial registration number: ChiCTR2100045258.Keywords
Funding Information
- Henan Provincial Key R&D Program (252102311155)
- Henan provincial Medical Science and technology research program (SBGJ202402053)
This publication has 32 references indexed in Scilit:
- Thrombolysis in lacunar stroke: Comparison of early neurological improvement and 90-day functional outcome with cardioembolic stroke without large-vessel occlusionJournal of Stroke and Cerebrovascular Diseases, 2025
- Efficacy and Safety of Intravenous rtPA in Ischemic Strokes Due to Small-Vessel Occlusion: Systematic Review and Meta-AnalysisTranslational Stroke Research, 2021
- Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP TrialJAMA Neurology, 2019
- Patients with Acute Lacunar Infarction Have Benefit from Intravenous ThrombolysisJournal of Stroke and Cerebrovascular Diseases, 2019
- Intravenous tissue plasminogen activator in acute branch atheromatous disease: Does it prevent early neurological deterioration?Journal of Clinical Neuroscience, 2016
- Intravenous thrombolysis for acute ischemic strokeDiagnostic and Interventional Imaging, 2014
- Treatment Outcomes of Tissue Plasminogen Activator Infusion for Branch Atheromatous DiseaseJournal of Stroke and Cerebrovascular Diseases, 2013
- Systemic inflammation and stroke: aetiology, pathology and targets for therapyBiochemical Society Transactions, 2007
- Long-term prognosis after lacunar infarctionThe Lancet Neurology, 2003
- Intravenous Thrombolysis With Recombinant Tissue Plasminogen Activator for Acute Hemispheric StrokeJAMA, 1995